Abbott Shares Jump 12% on Raised 2026 Profit Outlook
Abbott Laboratories raised its full-year earnings forecast and reported better-than-expected second-quarter profit, signaling that its medical device pipeline is translating into accelerating growth.
Abbott Laboratories reported adjusted second-quarter earnings per share of $1.31 on the back of robust demand, pushing its shares up 12%. The healthcare conglomerate capitalized on underlying business strength to raise its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from a prior estimate of $5.38 to $5.58. GAAP diluted earnings per share for the quarter landed at $0.53.
The upward revision signals renewed confidence in the company's near-term growth trajectory. "Our second-quarter results reflect the momentum we are building,” said Robert B. Ford, chairman and chief executive officer of Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
While the earnings target moved higher, Abbott held steady on its full-year comparable sales growth guidance of 6.5% to 7.5%. This dynamic suggests the improved profitability is being driven by favorable product mix and operational execution rather than solely relying on top-line expansion.
Pipeline validates outlook
A steady stream of regulatory and clinical developments supports management's optimistic stance on the second half. In May, Abbott secured a CE Mark for Libre Duo, positioning it as the world’s first dual glucose-ketone biowearable sensor. For investors, this device is critical because it expands Abbott's footprint in the continuous monitoring market by addressing diabetic ketoacidosis, a serious condition caused by rising ketone levels.
The company's cardiovascular division is also advancing key growth drivers. Abbott completed enrolment in its TECTONIC US pivotal trial for a coronary intravascular lithotripsy system, a technology designed to fracture severe calcium build-up in coronary arteries before stent implantation. Addressing heavily calcified lesions represents a significant market opportunity for interventional cardiology.
Abbott also submitted its Amulet 360 left atrial appendage device to the US Food and Drug Administration for approval, aiming to capture share in the structural heart market. Clinical data presented at the Heart Rhythm Society conference in April further validated this pipeline. Late-breaking results from four trials demonstrated strong clinical outcomes across Abbott's pulsed field ablation and conduction system pacing portfolios, reinforcing the long-term revenue potential of its device franchise.
